Why Am I Not Losing Weight on Compounded Tirzepatide / Semaglutide? (Plateau Decision Tree)

“Why am I not losing weight on compounded tirzepatide?” is one of the fastest-growing patient searches in the GLP-1 space — and the answer almost always depends on which branch of the problem you are in. The frustration is real; the causes are distinct; and most of them are either expected or fixable. This article maps five specific branches — from early titration through true non-response through compound quality concerns — so you can self-classify and know what to bring to your prescriber. Every clinical threshold cited below is sourced from verbatim FDA label language or from the primary pivotal trials (STEP-1, SURMOUNT-1, STEP-4, SURMOUNT-5).

TL;DR — 5 branches + how to classify yourself

Before working through each branch in detail, here is the rapid classification guide. Identify the statement that best describes your situation and jump to that branch.

What “plateau” actually means in trial data

The word “plateau” is used loosely by patients and clinicians alike, but the clinical trial data gives it a precise meaning. In both STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide), the weight-loss curves follow a characteristic shape: steep early loss during titration and the first months at maintenance dose, then a pronounced flattening in the second half of the trial. This flattening is not a sign the medication has stopped working — it is the documented pharmacological ceiling of the drug in the trial population.

STEP-1 weight-loss trajectory (semaglutide 2.4 mg)

STEP-1 (PMID 33567185) enrolled 1,961 adults with obesity or overweight without type 2 diabetes. The semaglutide 2.4 mg arm achieved a mean weight loss of -14.9% of body weight at week 68. The Wegovy prescribing information Section 14 (Clinical Studies) describes the trajectory as follows:

“The estimated mean change from baseline in body weight at week 68 was -14.9% for WEGOVY compared to -2.4% for placebo… The time to reach a clinically meaningful weight reduction of 5% was 8 weeks for WEGOVY.”

Source: WEGOVY US Prescribing Information, Section 14.1 (Study 1), DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Novo Nordisk Inc. Verified 2026-05-10.

Critically, Figure 2 of the STEP-1 publication shows the weight-loss curve flattening substantially after approximately week 40-48, with minimal additional mean loss between weeks 48 and 68. A patient who has lost 12% by week 40 and only 14.9% by week 68 is not “stalling” in any clinical sense — they are on the expected curve.

SURMOUNT-1 weight-loss trajectory (tirzepatide)

SURMOUNT-1 (PMID 35658024) enrolled 2,539 adults with obesity or overweight without type 2 diabetes. The Zepbound prescribing information Section 14 (Clinical Studies) reports:

“The mean change in body weight from baseline to week 72 was -20.9% for ZEPBOUND 15 mg, -19.5% for ZEPBOUND 10 mg, and -15.0% for ZEPBOUND 5 mg compared to -3.1% for placebo.”

Source: ZEPBOUND US Prescribing Information, Section 14.1, DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, Eli Lilly and Company. Verified 2026-05-10.

Figure 1 of the SURMOUNT-1 publication shows the curve flattening around weeks 52-72 for all three active doses. The plateau is biological — the drug's appetite-suppressive and metabolic effects have reached their equilibrium with the body's compensatory mechanisms. This is not a sign that the medication needs to be stopped or switched; STEP-4 data (below) confirms that stopping the medication at plateau leads to significant weight regain.

Branch 1: Early titration — weeks 1-12 (likely too early to evaluate)

The most common patient misclassification is declaring non-response during the titration phase, before the medication has reached its full maintenance dose and pharmacokinetic steady-state.

Consider the titration timelines:

• Semaglutide (Wegovy/compounded): titration runs from 0.25 mg to 0.5 mg to 1 mg to 1.7 mg to 2.4 mg, spending approximately 4 weeks at each step. The maintenance dose (2.4 mg) is not reached until approximately week 17-20. Many compounding prescriptions run at custom schedules that extend this further.
• Tirzepatide (Zepbound/compounded): titration runs from 2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg, with a minimum 4 weeks at each step. The maximum maintenance dose (15 mg) is not reached until approximately week 21-24 at the fastest FDA-label schedule.

In STEP-1 at week 12, participants had not yet reached the full 2.4 mg maintenance dose — the expected mean weight loss at that point in the trial was in the range of 4-7%, far below the final 14.9% at week 68. The implication: if you are at week 8 and have lost 3%, you may be precisely on the expected trial curve. The weeks 8-52 period is the steepest-loss window.

What to do in Branch 1

• Continue the prescribed titration schedule. Do not escalate faster than the FDA-label minimum 4-week intervals without prescriber guidance — accelerated escalation increases GI side-effect risk without proportionally faster weight loss.
• Track progress from the start date, not from when you began to feel appetite suppression. The scale typically lags the pharmacological effect by 2-4 weeks.
• Benchmark at week 16 at maintenance dose, not at week 12 during titration. That is the FDA label's non-response evaluation window.
• Consider whether compounded doses match the brand-name titration ladder. Some compounding prescriptions use different dose increments — confirm with your prescriber that your dose ladder is appropriate.

Branch 2: Maintenance dose, modest loss — biological plateau

Not every patient achieves the trial mean. GLP-1 medications produce a wide distribution of responses, and the distribution in both STEP-1 and SURMOUNT-1 includes patients with much smaller-than-average responses.

In STEP-1, the bottom quartile of semaglutide 2.4 mg responders lost approximately 5% or less at 68 weeks — a modest result that nonetheless represents real metabolic benefit. These patients are not non-responders in the clinical label sense; they are low-end responders. SURMOUNT-1 similarly shows a distribution of responses in which roughly 9% of tirzepatide 15 mg participants lost less than 5% of body weight — these are documented in the trial as the non-response tail, but the remaining 91% vary widely around the mean.

If you are at maintenance dose, have passed 16 weeks, and are showing 5-10% weight loss with a flattening curve — you are in the biological plateau range and are a low-end responder, not a non-responder. The medication is working. The question is whether the achieved weight loss is sufficient for your clinical goals and whether further optimization (dose escalation if not at maximum, behavioral interventions) is warranted.

Optimizing response in Branch 2

• Confirm you are at the maximum tolerated dose. If you are on tirzepatide 10 mg and experiencing minimal response, escalating to 12.5 mg or 15 mg — per SURMOUNT-1 dose-response data — would be expected to produce additional loss. The 15 mg dose produced -20.9% versus -19.5% at 10 mg.
• Evaluate caloric intake honestly. GLP-1 medications reduce appetite — they do not eliminate it, and they do not override a caloric surplus. If appetite suppression is modest at your current dose, track food intake for 2 weeks before concluding the medication is insufficient.
• Add resistance training. See our exercise pairing + lean mass preservation guide. Muscle gain during GLP-1 therapy can maintain the scale at a plateau while body composition continues to improve.
• Discuss medication timing with your prescriber. Some patients report better appetite suppression from morning versus evening injections; evidence is anecdotal but the discussion with your prescriber is low-risk.

Branch 3: True non-response after 16+ weeks at full maintenance dose

True non-response — less than 5% weight loss after 16 weeks at the maintenance dose — is uncommon but documented. The Wegovy prescribing information contains an explicit non-response criterion:

“Evaluate the benefit of continuing WEGOVY in patients who have not achieved at least 5% weight loss after 16 weeks of treatment at the maintenance dose.”

Source: WEGOVY US Prescribing Information, Section 16 (How Supplied / Storage and Handling), DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Novo Nordisk Inc. Verified 2026-05-10.

This criterion applies at the full maintenance dose (2.4 mg for Wegovy), not during the titration period. A patient who has been on tirzepatide but has not yet reached the maintenance dose (15 mg) is not yet in the non-response evaluation window. The 16-week clock starts when you reach your prescribed maintenance dose — not from the first injection.

In SURMOUNT-1, approximately 9% of patients on tirzepatide 15 mg fell below 5% weight loss at week 72. For semaglutide (STEP-1), approximately 14% of patients on 2.4 mg fell below 5% at week 68. These are real rates — not outliers — and they represent patients for whom the drug did not produce a clinically meaningful response despite full-dose sustained therapy.

What to do in Branch 3

• Discuss the result with your prescriber explicitly. The FDA label non-response criterion is the correct framing. Bring it to the appointment.
• Consider switching drug class. Non-response to semaglutide (GLP-1 single agonist) does not predict non-response to tirzepatide (dual GIP+GLP-1 agonist). SURMOUNT-5 (PMID 40353578) demonstrated tirzepatide produced meaningfully greater weight loss than semaglutide in a head-to-head comparison. A patient who is a true non-responder to semaglutide may respond to tirzepatide.
• Rule out adherence and technique issues first (see Branch 4 below and the adherence checklist in Section 8). Technical errors in injection or dose preparation can look like non-response.
• Rule out secondary causes. Hypothyroidism, Cushing syndrome, undiagnosed sleep apnea, and polycystic ovary syndrome (PCOS) can all reduce GLP-1 response. Ask your prescriber for a metabolic workup if you have not had one.
• Do not increase dose beyond label maximum without prescriber guidance. Self-escalating above 2.4 mg semaglutide or 15 mg tirzepatide without prescriber oversight is not supported by trial evidence and increases adverse-event risk.

Branch 4: Losing weight, then stopping despite continuing therapy

Branch 4 describes a patient who had a period of active weight loss, then plateaued or gained weight while staying on the same medication at the same dose. This is the most common clinical complaint and the most misattributed to compound quality.

The most likely explanations, in rough order of probability:

Diet drift

GLP-1 medications suppress appetite — they do not eliminate the rewarding properties of calorie-dense food. Over months of therapy, many patients gradually reintroduce portion sizes or food categories that offset the medication's caloric impact. This happens incrementally and often unconsciously. The medication may be working exactly as expected, but the dietary baseline has drifted enough to cancel the deficit.

The STEP-4 trial (PMID 34717826) provides the most important context here. Patients on semaglutide who had already lost weight through week 20 were randomized to continue semaglutide or switch to placebo. Those who continued semaglutide lost an additional -7.9% of body weight from week 20 to week 68. Those who switched to placebo regained +6.9%. The medication matters — but the dietary environment during maintenance determines whether the medication drives continued loss or merely maintains the current weight.

Activity drift

Physical activity levels commonly decline during long-term GLP-1 therapy as patients lose motivation once initial progress slows. GLP-1 medications do not independently increase energy expenditure to a clinically meaningful degree — the weight loss is primarily driven by caloric restriction from appetite suppression. If activity decreases while intake stabilizes, the overall deficit narrows and the plateau accelerates.

Is compound quality the cause?

Compound quality is a legitimate but less likely explanation in Branch 4 — specifically when the patient was actively losing on the same pharmacy's supply and then stalled. If the pharmacy, lot number, and preparation method have not changed, a sudden decline in compound quality mid-therapy is less probable than the behavioral explanations above. However, if your pharmacy changed suppliers, reformulated, or shipped from a new lot that coincided with the stall, a quality concern is worth investigating.

The more suspicious scenario for compound quality is Branch 5, described next. If you are in Branch 4 and have ruled out diet and activity drift, see the compound verification steps in Branch 5 and the adherence checklist in Section 8.

Branch 5: Lost weight on brand-name, stalled on compounded

Branch 5 is the scenario where compound quality is the primary concern: you had documented weight loss on brand-name Wegovy or Zepbound, then switched to a compounded preparation and your progress stopped or reversed.

This pattern is the strongest evidence of a compound quality concern because the confounders that explain Branches 1-4 are controlled: you know the drug works for you, your diet and activity did not change at the time of the switch, and the only variable that changed was the source of the medication.

Compound quality variables

Compounded GLP-1 preparations are not FDA-approved products. Quality depends entirely on the specific 503A or 503B pharmacy's practices. The variables that can differ between a compounded preparation and the brand-name product include:

• Dose accuracy. Unlike FDA-approved products, which undergo rigorous manufacturing quality control including potency testing of every batch, compounded preparations are tested at the pharmacy level. Quality control practices vary significantly across pharmacies. A preparation labeled as 5 mg tirzepatide may contain more or less of the active ingredient than labeled.
• Degradation from improper storage or shipping. GLP-1 peptides are temperature-sensitive. Wegovy and Zepbound require refrigeration (36-46°F / 2-8°C). Exposure to temperatures above 77°F / 25°C for extended periods can degrade the peptide and reduce potency. Compounded preparations — especially those shipped without adequate cold-chain packaging — are at higher risk of heat-induced degradation in transit.
• Additives (B12, NAD+, other peptides). Many compounding pharmacies add vitamin B12, NAD+, or other compounds to their GLP-1 formulations. These additives are not present in the FDA-approved branded versions and have no clinical trial evidence demonstrating benefit to weight loss. There is no evidence that B12 or NAD+ improves GLP-1 efficacy. However, additives can affect formulation stability — a pharmacist who changes additives or their concentrations between lots may inadvertently alter the active ingredient's stability.
• Reconstitution errors. Lyophilized (freeze-dried) compounded preparations require reconstitution with bacteriostatic water before use. Reconstitution errors — wrong volume, wrong water, contaminated syringe — can significantly alter the effective dose. For details, see our compounded GLP-1 reconstitution guide.

How to verify your compounded medication

If you are in Branch 5, take these verification steps before asking your prescriber to switch back to brand-name or to a different compounding pharmacy:

1. Request the lot number for your current supply from your pharmacy. Document when the lot changed relative to when your progress stalled.
2. Request the Certificate of Analysis (COA) from your pharmacy for the current lot. A COA is a third-party analytical laboratory report confirming the active ingredient identity, concentration, and absence of contaminants. A legitimate compounding pharmacy can provide this within 24-48 hours.
3. Verify pharmacy licensure. Check your pharmacy's state pharmacy license status through the NABP (National Association of Boards of Pharmacy) e-Profile at nabp.pharmacy. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation as an additional quality signal.
4. Use our pharmacy verification tool. Our pharmacy legitimacy lookup walks through each verification step and checks known red flags for compounding pharmacies.
5. Do not switch pharmacies without prescriber input. Your prescriber needs to be aware of the quality concern, write a new prescription for the new pharmacy, and monitor your response after the switch. Do not self-direct this process.

Adherence variables to check (any branch)

Before attributing a plateau to compound quality or biological non-response, work through this adherence checklist. Any single item can silently reduce effective dose by 25-50%.

Missed doses and re-titration

The Wegovy prescribing information Section 2.1 contains specific guidance on missed doses:

“If a dose of WEGOVY is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible. If a dose of WEGOVY is missed and the next scheduled dose is less than 2 days away (48 hours), do not take the missed dose. Resume the regular once weekly dosing schedule.”

Source: WEGOVY US Prescribing Information, Section 2.1, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Novo Nordisk Inc. Verified 2026-05-10.

More importantly for plateau patients: gaps of more than 7 consecutive days off the medication result in meaningful plasma level decline below the therapeutic window. In clinical practice, gaps exceeding 7 days are typically managed by re-titrating from a lower dose to avoid rebound GI side effects, which effectively delays return to full maintenance-dose effect. If you have had multiple gaps of this length, your effective total weeks at therapeutic dose may be significantly less than your calendar weeks on the prescription.

Refrigeration and storage

• Keep vials refrigerated at 36-46°F (2-8°C) until use. Do not freeze.
• Do not leave vials at room temperature for extended periods — brand products allow up to 28 days at room temperature (below 77°F / 25°C), but this guideline applies to the branded product and may not apply to your specific compounded formulation's stability testing. Ask your pharmacy for the room-temperature beyond-use date.
• Heat exposure during shipping is a common source of potency loss in compounded preparations. If your shipment arrived warm or was delayed during transit in hot weather, the preparation may have been compromised.

Injection technique

• Inject into subcutaneous fat (not muscle). The abdomen, outer thigh, and upper arm are the standard sites. Injecting into muscle accelerates absorption but reduces the sustained pharmacokinetic profile the drug was tested at.
• Rotate injection sites. Injecting consistently into the same site can create lipohypertrophy (fatty tissue buildup) that slows absorption.
• For compounded vials: confirm your injection volume calculation is correct. A 2.5 mg dose from a 10 mg/mL vial requires drawing 0.25 mL, not 0.25 units. Concentration math errors are the most common source of under-dosing in self-administered compounded preparations.

Food log honesty

Studies consistently show that patients under-report caloric intake by 30-50% when self-reporting without tools. A patient convinced they are in a deficit because their appetite is suppressed may still be consuming maintenance calories from high-density foods that are not registering as significant. Two weeks of logged intake using a validated app (MyFitnessPal, Cronometer) provides a more accurate picture than subjective assessment.

Body composition vs scale weight

Scale weight plateau does not always equal no progress. GLP-1 therapy combined with resistance training frequently produces a scenario where fat mass decreases while lean muscle mass increases, leaving scale weight approximately stable. This is the ideal body composition outcome — but it reads as a plateau on the scale and is frequently misinterpreted as treatment failure.

If you are engaged in regular resistance training during GLP-1 therapy, consider using a body composition measure beyond scale weight:

• DEXA scan — the gold standard for fat mass vs lean mass quantification; costs $50-150 out of pocket at most radiology centers without a prescription.
• Bioelectrical impedance analysis (BIA) — available on consumer smart scales (Withings, Garmin, InBody). Less precise than DEXA but sufficient to track trends over weeks.
• Waist circumference — a single tape measurement at the navel level, taken under consistent conditions. Waist reduction with stable scale weight is a reliable sign that fat redistribution is occurring. STEP-1 and SURMOUNT-1 both tracked waist circumference as a secondary endpoint and showed significant reductions independent of scale weight.
• Progress photos at 30-day intervals under consistent lighting conditions. Visual change often precedes and exceeds what the scale reflects when muscle gain is involved.

The practical recommendation: if you are at a scale plateau and are actively strength training, measure waist circumference and consider a DEXA scan before concluding the medication is not working. A 2 cm waist reduction with a stable scale means fat is being replaced by lean mass — a success, not a failure.

When to consider switching drugs

Drug switching is a prescriber decision, but the evidence base supports raising the question in specific circumstances.

The strongest evidence for switching comes from SURMOUNT-5 (PMID 40353578), the first head-to-head randomized controlled trial of tirzepatide versus semaglutide in patients with obesity. Tirzepatide produced statistically and clinically greater weight loss than semaglutide 2.4 mg. Patients on tirzepatide 15 mg lost approximately 20.2% of body weight versus approximately 13.7% for semaglutide 2.4 mg — a difference of approximately 6.5 percentage points.

The mechanism argument for switching from semaglutide to tirzepatide in non-responders: tirzepatide is a dual agonist (GIP receptor plus GLP-1 receptor), while semaglutide is a selective GLP-1 receptor agonist. The additional GIP agonism may drive weight loss through pathways that are not activated by semaglutide alone — meaning a partial responder to semaglutide may have meaningful remaining response capacity that tirzepatide can engage.

Consider discussing a switch with your prescriber when:

• You meet the Wegovy non-response criterion: less than 5% weight loss after 16 weeks at full maintenance dose, after ruling out adherence and technical errors.
• You are on maximum-dose semaglutide (2.4 mg) with modest response and have confirmed adherence.
• You are in Branch 5 and have confirmed a compound quality concern — a switch back to branded drug is the definitive test.

When to consider stopping

Stopping a GLP-1 medication is not equivalent to failing a treatment. STEP-4 (PMID 34717826) provides the clearest data on what happens when patients stop semaglutide after achieving weight loss: they regain a substantial portion of the lost weight within 48 weeks. This means stopping should be a deliberate, prescriber-supervised decision — not a response to frustration with plateau.

Stopping is a reasonable clinical option when:

• True non-response is confirmed — less than 5% weight loss after 16 weeks at maintenance dose, with adherence and technical errors ruled out, and a trial of dose maximization completed. The benefit-risk balance is unfavorable when side effects continue and efficacy is absent.
• Ongoing GI side effects outweigh benefit. If nausea, vomiting, or diarrhea are severe enough to impair daily function and have not resolved after an extended titration hold or dose reduction, stopping is appropriate. Discuss alternative mechanisms (Saxenda for lower GI burden, Contrave for a non-GLP-1 oral option) with your prescriber.
• A significant procedure or medical event requires temporary discontinuation per the prescriber's guidance — for example, elective surgery may require a washout period to normalize gastric emptying.

Never stop a GLP-1 medication abruptly because of a scale plateau without first working through the five branches in this guide and discussing the picture with your prescriber. A plateau at month 8-12 is not a reason to stop — it is the expected pharmacological plateau documented in every GLP-1 pivotal trial.

Frequently asked questions

Why am I not losing weight on tirzepatide?

The most common reasons, in order of probability: (1) you are still in the titration phase and the dose has not reached full therapeutic effect — at week 12, the expected mean loss in SURMOUNT-1 was approximately 4-7%, far below the 20.9% final result at week 72; (2) you have hit the biological plateau that occurs in most patients around weeks 52-72 at maintenance dose; (3) diet drift has offset the medication's appetite-suppressive effect; (4) missed doses exceeding 7 days have reduced effective plasma levels below the therapeutic window. True non-response (less than 5% at 16 weeks on maintenance dose) affects approximately 9% of tirzepatide 15 mg patients in SURMOUNT-1 and warrants prescriber discussion about switching or investigation for secondary causes.

How long does it take for tirzepatide to work?

SURMOUNT-1 (PMID 35658024) shows meaningful weight loss beginning at weeks 4-8, with the steepest loss period between weeks 8 and 52. The weight-loss curve flattens significantly after week 52 at maintenance dose, with maximum weight loss typically reached between weeks 60-72. At week 12 (still in titration for most patients), mean weight loss in SURMOUNT-1 was approximately 4-7% depending on dose. The final mean at week 72 for the 15 mg group was -20.9%. Expecting final-curve results before week 52 is the most common source of plateau misclassification.

Is my compounded tirzepatide bad?

Compound quality is a legitimate but secondary concern for most patients on compounded GLP-1. If you were previously losing on the same pharmacy's supply and stalled without changing pharmacies or lots, the most likely explanations are biological plateau, diet drift, or adherence issues — not compound failure. Compound quality becomes the primary concern specifically when: (a) you switched from brand-name Zepbound or Wegovy to compounded and progress stopped, or (b) your pharmacy changed lots or formulation coinciding with the stall. In either case, request the lot number and COA from your pharmacy and use our pharmacy legitimacy lookup tool.

Should I switch from Wegovy to Zepbound?

Switching from semaglutide to tirzepatide is a clinical decision supported by SURMOUNT-5 (PMID 40353578) evidence that tirzepatide produced meaningfully greater weight loss than semaglutide 2.4 mg in a head-to-head randomized trial. Consider raising the question with your prescriber if: (1) you meet the Wegovy non-response criterion (less than 5% weight loss after 16 weeks at the 2.4 mg maintenance dose); (2) you are at maximum tolerated semaglutide dose with modest response and confirmed adherence. The switch requires a new prescription, a re-titration schedule, and monitoring — it is not a self-directed decision.

What is a normal plateau on a GLP-1?

A biological plateau — where the weight-loss curve flattens despite continued therapy — is documented in both STEP-1 and SURMOUNT-1. In STEP-1, the semaglutide 2.4 mg curve flattens around weeks 40-48 with minimal additional mean loss to week 68 (PMID 33567185). In SURMOUNT-1, the tirzepatide 15 mg curve flattens around weeks 52-72 (PMID 35658024). This plateau represents the pharmacological ceiling of the drug — not failure, not compound quality issues, and not a reason to stop. STEP-4 (PMID 34717826) confirms that stopping at the plateau leads to significant weight regain.

How do I verify my compounded medication?

Request from your pharmacy: (1) the lot number for your current supply; (2) the Certificate of Analysis (COA) from a third-party analytical laboratory confirming active-ingredient identity and concentration; (3) the pharmacy's state license number. Verify licensure through the NABP e-Profile at nabp.pharmacy. Look for PCAB accreditation as a quality signal. Use our pharmacy legitimacy lookup tool for a step-by-step walkthrough.

Can compounded GLP-1 additives like B12 affect weight loss?

There is no published clinical trial evidence that B12 or NAD+ additives in compounded GLP-1 preparations improve weight-loss outcomes. These additives are not present in the FDA-approved branded versions (Wegovy, Zepbound) and were not tested in STEP-1 or SURMOUNT-1. If you switched from a compounded preparation with B12 to one without (or vice versa) and observed a response change, the change is most likely attributable to other formulation variables — not the additive itself.

Related articles

• Compounded tirzepatide vs compounded semaglutide — full comparison of the two compounded options: efficacy, side effects, regulatory status, and cost. Covers the compounded drug landscape post-February 2025 FDA enforcement discretion end.
• GLP-1 fatigue: onset, mechanism, and management — if your plateau coincides with fatigue or low energy, this companion article covers the five biological mechanisms behind GLP-1 fatigue, verbatim FDA-label adverse-reaction rates, and the management strategies that actually work.
• Foundayo vs Zepbound switch and dose-equivalence guide — if plateau at maintenance tirzepatide dose prompts considering a different mechanism (oral GLP-1 vs injection), this guide covers the Foundayo-to-Zepbound and Zepbound-to-Foundayo switch decision.
• GLP-1 side-effect Q&A hub — comprehensive coverage of every common GLP-1 adverse reaction, from the FDA labels and trial adverse-event tables.
• Exercise pairing + lean mass preservation on GLP-1 — scale plateau with stable waist circumference often means muscle gain is offsetting fat loss. This guide covers the evidence-based resistance training protocols for GLP-1 users.
• Pharmacy legitimacy lookup tool — step-by-step compound pharmacy verification: NABP e-Profile, PCAB accreditation check, COA request template.

Important disclaimer. This article is educational and does not constitute medical advice. The decision tree above is a framework for organizing a conversation with your prescriber — it does not replace clinical evaluation. Every clinical claim is sourced from the verbatim DailyMed FDA labels for Wegovy and Zepbound (SetIDs verified 2026-05-10) or from PubMed-indexed primary-source publications cited in the References section. Do not stop, start, or change any medication without speaking to a licensed prescriber. Do not self-direct a pharmacy switch without prescriber oversight. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment.